Mohammad Jad Moussa: Overview of our abstracts for ASCO GU 2025
Mohammad Jad Moussa, Oncology Fellow at MD Anderson Cancer Center, shared a post on X:
“Thrilled to be heading to ASCO GU 2025 with my mentors (Omar Alhalabi and Matt Campbell) and an outstdanding group of MD Anderson Cancer Center trainees with a very strong show-up, mentored by our exceptional faculty!
Quick overview of our abstracts – A thread
Abs 818 (Mentored by Matt Campbell and Omar Alhalabi): Our Original Research on single-agent ICIs in dMMR/MSI-H LA/mUTUC -> Potential predictive and prognostic biomarker? Thank you Conquer Cancer Foundation for recognition
Abs 558 (Nizar Tannir and Omar Alhalabi): Nivo/ipi in vhRCC!
Neha Venkatesh (Abstract 116): Mentored by Andy Hahn.
Study of common CV risk assessment tools in men on pre-op hormonal therapy in advanced prostate cancer.
Kabir Grewal (Abstract 545): Mentored by Andy Hahn
Association of skeletal muscle mass with PFS in pts with metastatic ccRCC tx with 1L nivo/ipi –> New insights on muscle mass impact on tumor microenvironment?
Nazli Dizman (Abstract 503): Mentored by Martin Voss and Pavlos Msaouel
Impact of local definitive therapy (LDT) on treatment-free interval in patients with metachronous metastatic chromophobe RCC –> Role in delaying systemic therapy?
Hongchao He (Abstarct 462): Mentored by Dr. Bilal A. Siddiqui
Single-institution characterization of immune-related adverse events (irAEs), patterns of hospitalizations and readmissions in pts with GU cancers treated with immunotherapy.
Alexander Sherry (Abstract 140): Mentored by Dr Chad Tang
Results of Phase II EXTEND basket of patients with oligometastatic prostate cancer with continuous androgen deprivation therapy (cADT) + insights of added metastasis-directed therapy (MDT) on immunity.
Joelle Allam (Abstract 456): Mentored by Dr. Ryan Huey
Characterization of cancers of unknown primary (CUP) with renal phenotype as a distinct subset of CUP, with unique immunophenotyping and molecular profiles.
Patrick Carriere (Abstract 799): Mentored by Dr. Comron Hassanzadeh
Description of the potential of metastasis-directed therapy (MDT) in improving cancer control in oligometastatic UC/UTUC alongside systemic treatment
Stepan Esegian – upcoming Hem/Onc fellow of MD Anderson Cancer Center (Abstract 447): Mentored by Pavlos Msaouel
Analysis of the National Inpatient Sample (2006-2021) to assess trends in CN utilization for mRCC and analyze associated social and demographic factors
Don’t be shy to pass by and learn more! More details on these abstracts found at meetings.asco.org.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023